Renata receives European approval for Levothyroxine tablets
Renata PLC has secured approval for its Levothyroxine Sodium tablets through the European Union Decentralised Procedure in Ireland, Germany, Italy, Poland, Portugal and Malta, marking a significant milestone in the company's international expansion.
The approval in six European Union member states demonstrates Renata PLC's adherence to European regulatory standards and underscores its ability to deliver high-quality medicines to patients in international markets.
Levothyroxine is a synthetic thyroid hormone commonly prescribed for hypothyroidism and other thyroid disorders.
Keep updated, follow The Business Standard's Google news channel
The company noted that even minor variations in dosage or product quality can impact clinical outcomes for patients using Levothyroxine, given the medicine's critical role in regulating metabolic function.
Levothyroxine Sodium tablets are produced at Renata PLC's European Union Good Manufacturing Practice-approved potent product facility, supported by stringent quality controls and research and development-led formulation, according to the company.
In Bangladesh, Renata PLC markets Levothyroxine under the brand name "Thyrox".
Renata PLC stated its commitment to ensuring safe and reliable access to Levothyroxine in the newly approved European markets, as it has in Bangladesh.
